+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypercalcemia Treatment - Global Market Trajectory & Analytics

  • ID: 5309461
  • Report
  • April 2021
  • Region: Global
  • 131 pages
  • Global Industry Analysts, Inc
1 of 2
Global Hypercalcemia Treatment Market to Reach $19.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Hypercalcemia Treatment estimated at US$10.7 Billion in the year 2020, is projected to reach a revised size of US$19.9 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Bisphosphonates, one of the segments analyzed in the report, is projected to record a 9.3% CAGR and reach US$13.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Calcitonin segment is readjusted to a revised 8.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.2 Billion, While China is Forecast to Grow at 8.7% CAGR

The Hypercalcemia Treatment market in the U.S. is estimated at US$3.2 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Glucocorticoids Segment to Record 10.3% CAGR

In the global Glucocorticoids segment, USA, Canada, Japan, China and Europe will drive the 10.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$823.3 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.3 Billion by the year 2027.

Select Competitors (Total 38 Featured):
  • AbbVie, Inc.
  • Amgen, Inc.
  • DiaSorin SpA
  • Fujirebio Europe NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Opko Health, Inc.
  • Rockwell Medical
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Hypercalcemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Hypercalcemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Hypercalcemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Glucocorticoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Calcimimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Calcimimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Calcimimetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Denusomab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Denusomab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Denusomab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 19: USA Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 22: Canada Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 25: Japan Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Japan Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Japan 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 28: China Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: China Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: China 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 31: Europe Current & Future Analysis for Hypercalcemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Hypercalcemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Hypercalcemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 34: Europe Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Europe Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Europe 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 37: France Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: France Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: France 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 40: Germany Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Germany Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Germany 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 43: Italy Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Italy Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Italy 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 46: UK Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: UK Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: UK 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 49: Rest of Europe Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of Europe Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Rest of Europe 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 52: Asia-Pacific Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Asia-Pacific Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Asia-Pacific 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
  • Table 55: Rest of World Current & Future Analysis for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Rest of World Historic Review for Hypercalcemia Treatment by Segment - Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Rest of World 15-Year Perspective for Hypercalcemia Treatment by Segment - Percentage Breakdown of Value Sales for Bisphosphonates, Calcitonin, Glucocorticoids, Calcimimetic Agents and Denusomab for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 38
Note: Product cover images may vary from those shown
Adroll
adroll